Boston Scientific Corporation BSX

43.92 (0.76) (1.70%) as of 25 Sep
Market cap
$64.7B
P/E
17.7×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

Boston Scientific Corporation (BSX) Return on equity

Boston Scientific Corporation's return on equity over the twelve months to 30 June 2026 was 15.4%, up 2.9 percentage points from fiscal 2025 (12.5%). Over the past ten years it has ranged from −3.74% (fiscal 2015) to 41.6% (fiscal 2019); the current reading is higher than 82% of that period. That is above the Medical Devices industry median of −15.3% and above the Healthcare sector median of −32.0%.

Return on equity, annual

Annual

Period Return on equity Change (points)
FY2025 12.5% 3.55
FY2024 8.92% 0.46
FY2023 8.46% 4.71
FY2022 3.75% (2.42)
FY2021 6.17% 6.96
FY2020 −0.79% (42.38)
FY2019 41.6% 20.35
FY2018 21.2% 19.73
FY2017 1.51% (3.81)
FY2016 5.32% 9.06

Against its own ten years

Low −3.74% High 41.6%
Ten-year median 6.17%
Current reading's percentile 82

Return on equity against peers

Company Return on equity
DXCM DexCom, Inc. compare 38.5%
GEHC GE HealthCare Technologies Inc. compare 19.2%
SYK Stryker Corporation compare 16.5%
BSX Boston Scientific Corporation 15.4%
STE STERIS plc compare 11.4%
ABT Abbott Laboratories compare 10.6%
MDT Medtronic PLC compare 10.6%
PHG Koninklijke Philips N.V. compare 10.2%
EW Edwards Lifesciences Corporation compare 9.42%
Medical Devices industry median −15.3%
Healthcare sector median −32.0%
Market median 1.76%

What Return on equity is

ROE shows how much profit a company earns for its shareholders on the equity they have in the business.

Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)

The full definition of Return on equity →

More on BSX